KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Total Non-Current Liabilities: 2010-2024

Historic Total Non-Current Liabilities for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $867.8 million.

  • Emergent BioSolutions' Total Non-Current Liabilities fell 10.46% to $835.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $835.9 million, marking a year-over-year decrease of 10.46%. This contributed to the annual value of $867.8 million for FY2024, which is 24.21% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Total Non-Current Liabilities of $867.8 million as of FY2024, which was down 24.21% from $1.1 billion recorded in FY2023.
  • Over the past 5 years, Emergent BioSolutions' Total Non-Current Liabilities peaked at $1.7 billion during FY2022, and registered a low of $867.8 million during FY2024.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $1.1 billion (2023), whereas its average is $1.2 billion.
  • Per our database at Business Quant, Emergent BioSolutions' Total Non-Current Liabilities soared by 36.06% in 2022 and then crashed by 34.09% in 2023.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Total Non-Current Liabilities stood at $1.4 billion in 2020, then fell by 6.70% to $1.3 billion in 2021, then skyrocketed by 36.06% to $1.7 billion in 2022, then tumbled by 34.09% to $1.1 billion in 2023, then fell by 24.21% to $867.8 million in 2024.